CA2868899C — Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles having mutation in the bcrabl gene
Assigned to Wyeth LLC · Expires 2017-06-13 · 9y expired
What this patent protects
The present invention provides 4-anilino-3-quinolinecarbonitrile compounds useful for treating a subject having an BcrAbl positive leukemia that is resistant to imatinib. Such leukemias include those having a resistance-associated amino acid mutation in the bcrabl protein, e.g. F…
USPTO Abstract
The present invention provides 4-anilino-3-quinolinecarbonitrile compounds useful for treating a subject having an BcrAbl positive leukemia that is resistant to imatinib. Such leukemias include those having a resistance-associated amino acid mutation in the bcrabl protein, e.g. F359V, H396P, I432T, F486S, M244V, L248V, G250E, Y253H, Y253F, E255K, K263E, L273M, T315I, F317L, and N331S.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.